We aimed to describe the features of 220 nonemergency (mild or common type) COVID-19 patients from a shelter hospital, as well as evaluate the efficiency of antiviral drug, Arbidol in their disease progressions. Basic clinical characteristics were described and the efficacy of Arbidol was evaluated based on gender, age, maximum body temperature of the patients. Basically, males had a higher risk of fever and more onset symptoms than females. Arbidol could accelerate fever recovery and viral clearance in respiratory specimens, particularly in males. Arbidol also contributed to shorter hospital stay without obvious adverse reactions. In the retrospective COVID-19 cohort, gender was one of the important factors affecting patient's conditions. Arbidol showed several beneficial effects in these patients, especially in males. This study brought more researches enlightenment in understanding the emerging infectious disease.

中文翻译：

---

武汉市东西湖收容医院220例非紧急COVID-19患者的抗病毒药Arbidol的临床特征和疗效：回顾性病例系列

我们旨在描述来自庇护医院的220名非紧急（轻度或普通型）COVID-19患者的特征，并评估抗病毒药物Arbidol在其疾病进展中的功效。描述了基本的临床特征，并根据患者的性别，年龄，最高体温评估了阿比多尔的疗效。基本上，男性比女性有更高的发烧风险和更多的发作症状。Arbidol可以加快呼吸道标本的发烧恢复和病毒清除，特别是在男性中。Arbidol还有助于缩短住院时间，而没有明显的不良反应。在回顾性COVID-19队列中，性别是影响患者状况的重要因素之一。Arbidol在这些患者中显示出多种有益作用，尤其是在男性中。